140. Dorabe syndrome Clinical trials / Disease details
Clinical trials : 104 / Drugs : 61 - (DrugBank : 14) / Drug target genes : 48 - Drug target pathways : 63
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-002484-25-PT (EUCTR) | 29/04/2019 | 19/11/2018 | A phase 2, multicenter, randomized, double-blind, controlled with placebo, to obtaine efficacy , safety and tolerability information for TAK-935 as an adjuntive therapy in pediatric patinets ((aged =2 and =17 years) with developmental and/or epileptic encephlopathies (Dravet syndrome and Lennox Gastaut) | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-935 (OV935) AS AN ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS WITH DEVELOPMENTAL AND/OR EPILEPTIC ENCEPHALOPATHIES (ELEKTRA) | Epileptic Encephalitis: Dravet and Lennox Gastuat syndrome (LGS);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TAK-935 INN or Proposed INN: None at this time Product Code: TAK-935 INN or Proposed INN: None at this time | Takeda Development Center Americas, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 126 | Phase 2 | United States;Portugal;Canada;Spain;Poland;Australia;Israel;China | ||
| 2 | EUCTR2018-002484-25-PL (EUCTR) | 14/03/2019 | 11/12/2018 | A phase 2, multicenter, randomized, double-blind, controlled with placebo, to obtaine efficacy , safety and tolerability information for TAK-935 as an adjuntive therapy in pediatric patinets ((aged =2 and =17 years) with developmental and/or epileptic encephlopathies (Dravet syndrome and Lennox Gastaut) | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-935 (OV935) AS AN ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS WITH DEVELOPMENTAL AND/OR EPILEPTIC ENCEPHALOPATHIES (ELEKTRA) | Epileptic Encephalitis: Dravet and Lennox Gastuat syndrome (LGS);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TAK-935 INN or Proposed INN: None at this time Product Code: TAK-935 INN or Proposed INN: None at this time | Takeda Development Center Americas, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 126 | Phase 2 | United States;Portugal;Canada;Spain;Poland;Australia;Israel;China |